Microbiota y quimioterapia intensiva en la leucemia mieloide aguda: Abordajes clínicos alternativos para mitigar la disbiosis bacteriana.
Palabras clave:
Leucemia mieloide aguda, quimioterapia, microbiota, disbiosis, terapias complementarias.Resumen
El objetivo de este trabajo fue realizar una revisión de la literatura con el fin de analizar diferentes terapias alternativas para atenuar la disbiosis de la microbiota intestinal durante el tratamiento con quimioterapia intensiva en pacientes con leucemia mieloide aguda. Para ello, se llevó a cabo una búsqueda bibliográfica en la base de datos PubMed con el propósito de recopilar información actualizada, utilizando como palabras clave leucemia mieloide aguda, quimioterapia, microbiota, disbiosis y terapias complementarias. Se excluyeron los artículos que no estuvieran disponibles en idioma inglés o español y se limitó la inclusión a aquellos desarrollados en los últimos años. La literatura revisada evidenció la existencia de terapias alternativas efectivas para disminuir la disbiosis bacteriana, como la desescalada de antibióticos, el uso de carbón activado oral, las betalactamasas exógenas y el trasplante de microbiota fecal; sin embargo, se resalta la necesidad de realizar estudios longitudinales a nivel local que permitan profundizar en estos hallazgos.
Descargas
Referencias
1. Rashidi A, Weisdorf DJ. Microbiota-based approaches to mitigate infectious complications of intensive chemotherapy in patients with acute leukemia. Transl Res. 2020; 220:167-81. DOI: 10.1016/j.trsl.2020.03.011.
2. Kantarjian HM, Kadia TM, DiNardo CD, Welch MA, Ravandi F. Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach. Cancer. 2021; 127(8):1186-207. DOI: 10.1002/cncr.33477.
3. Forsberg M, Konopleva M. AML treatment: conventional chemotherapy and emerging novel agents. Trends Pharmacol Sci. 2024; 45(5):430-48. DOI: 10.1016/j.tips.2024.03.005.
4. Sholl J, Sepich-Poore GD, Knight R, Pradeu T. Redrawing therapeutic boundaries: microbiota and cancer. Trends Cancer. 2022; 8(2):87-97. DOI: 10.1016/j.trecan.2021.10.008.
5. Renga G, Nunzi E, Stincardini C, Pariano M, Puccetti M, Pieraccini G, et al. CPX-351 exploits the gut microbiota to promote mucosal barrier function, colonization resistance, and immune homeostasis. Blood. 2024; 143(16):1628-45. DOI: 10.1182/blood.2023021380.
6. Strickland SA, Vey N. Diagnosis and treatment of therapy-related acute myeloid leukemia. Crit Rev Oncol Hematol. 2022;171:103607. DOI: 10.1016/j.critrevonc.2022.103607.
7. DiNardo CD, Erba HP, Freeman SD, Wei AH. Acute myeloid leukaemia. Lancet. 2023; 401(10393):2073-86. DOI: 10.1016/S0140-6736(23)00108-3.
8. Salvestrini V, Conti G, D’Amico F, Cristiano G, Candela M, Cavo M, et al. Gut Microbiome as a Potential Marker of Hematologic Recovery Following Induction Therapy in Acute Myeloid Leukemia Patients. Cancer Med. 2025; 14(3):e70501. DOI: 10.1002/cam4.70501.
9. Ferrara F, Lessi F, Vitagliano O, Birkenghi E, Rossi G. Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia. Cancers (Basel). 2019; 11(2):224. DOI: 10.3390/cancers11020224.
10. Kayser S, Levis MJ. The clinical impact of the molecular landscape of acute myeloid leukemia. Haematologica. 2023;108(2):308-20. DOI: 10.3324/haematol.2022.280801.
11. Hou K, Wu ZX, Chen XY, Wang JQ, Zhang D, Xiao C, et al. Microbiota in health and diseases. Signal Transduct Target Ther. 2022; 7(1):135. DOI: 10.1038/s41392-022-00974-4.
12. Manos J. The human microbiome in disease and pathology. APMIS. 2022; 130(12):690-705. DOI: 10.1111/apm.13225.
13. Ruff WE, Greiling TM, Kriegel MA. Host-microbiota interactions in immune-mediated diseases. Nat Rev Microbiol. 2020; 18(9):521-38. DOI: 10.1038/s41579-020-0367-2.
14. Lu Y, Yuan X, Wang M, He Z, Li H, Wang J et al. Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies. J Hematol Oncol. 2022 ;15(1):47. DOI: 10.1186/s13045-022-01273-9.
15. Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023; 16(1):29. DOI: 10.1186/s13045-023-01424-6.
16. Liu H. Emerging agents and regimens for AML. J Hematol Oncol. 2021; 14(1):49. DOI: 10.1186/s13045-021-01062-w.
17. Walti CS, Halpern AB, Xie H, Kiem ES, Chung EL, Schonhoff KG, et al. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms. Leukemia. 2023; 37(2):298-307. DOI: 10.1038/s41375-022-01786-9.
18. Maschmeyer G, Bullinger L, Garcia-Vidal C, Herbrecht R, Maertens J, Menna P, et al. Infectious complications of targeted drugs and biotherapies in acute leukemia. Clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL), a joint venture of the European Group for Blood and Marrow Transplantation (EBMT), the European Organization for Research and Treatment of Cancer (EORTC), the International Immunocompromised Host Society (ICHS) and the European Leukemia Net (ELN). Leukemia. 2022; 36(5):1215-26. DOI: 10.1038/s41375-022-01556-7.
19. Li Y, Zhang B, Jiang L, Cheng T, Cheng H, Qian P. Gut microbiota plays pivotal roles in benign and malignant hematopoiesis. Blood Sci. 2024; 6(4):e00200. DOI: 10.1097/BS9.0000000000000200.
20. Wang R, Yang X, Liu J, Zhong F, Zhang C, Chen Y, et al. Gut microbiota regulates acute myeloid leukaemia via alteration of intestinal barrier function mediated by butyrate. Nat Commun. 2022; 13(1):2522. DOI: 10.1038/s41467-022-30240-8.
21. Álvarez J, Fernández Real JM, Guarner F, Gueimonde M, Rodríguez JM, Saenz de Pipaon M, et al. Gut microbes and health. Gastroenterol Hepatol. 2021; 44(7):519-35. English, Spanish. DOI: 10.1016/j.gastrohep.2021.01.009.
22. McDonnell L, Gilkes A, Ashworth M, Rowland V, Harries TH, Armstrong D, et al. Association between antibiotics and gut microbiome dysbiosis in children: systematic review and meta-analysis. Gut Microbes. 2021; 13(1):1-18. DOI: 10.1080/19490976.2020.1870402.
23. Rashidi A, Kaiser T, Holtan SG, Rehman TU, Weisdorf DJ, Khoruts A, et al. Levaquin Gets a Pass. Biol Blood Marrow Transplant. 2020; 26(4):778-781. DOI: 10.1016/j.bbmt.2019.12.722.
24. Ziegler M, Han JH, Landsburg D, Pegues D, Reesey E, Gilmar C,et al; CDC Prevention Epicenters Program. Impact of Levofloxacin for the Prophylaxis of Bloodstream Infection on the Gut Microbiome in Patients With Hematologic Malignancy. Open Forum Infect Dis. 2019; 6(7):ofz252. DOI: 10.1093/ofid/ofz252.
25. Tinahones Madueño FJ. Nutrición y microbiota [Nutrition and microbiota]. Nutr Hosp. 2023; 40(Spec No2):9-11. Spanish. DOI: 10.20960/nh.04946.
26. Barrea L, Muscogiuri G, Frias-Toral E, Laudisio D, Pugliese G, Castellucci B, et al. Nutrition and immune system: from the Mediterranean diet to dietary supplementary through the microbiota. Crit Rev Food Sci Nutr. 2021; 61(18):3066-90. DOI: 10.1080/10408398.2020.1792826.
27. Altomare A, Di Rosa C, Imperia E, Emerenziani S, Cicala M, Guarino MPL. Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms. Nutrients. 2021; 13(5):1506. DOI: 10.3390/nu13051506.
28. D’Amico F, Biagi E, Rampelli S, Fiori J, Zama D, Soverini, et al. Enteral Nutrition in Pediatric Patients Undergoing Hematopoietic SCT Promotes the Recovery of Gut Microbiome Homeostasis. Nutrients. 2019 ;11(12):2958. DOI: 10.3390/nu11122958.
29. Li S, Zhu S, Yu J. The role of gut microbiota and metabolites in cancer chemotherapy. J Adv Res. 2024; 64:223-35. DOI: 10.1016/j.jare.2023.11.027.
30. Fernandes MR, Aggarwal P, Costa RGF, Cole AM, Trinchieri G. Targeting the gut microbiota for cancer therapy. Nat Rev Cancer. 2022; 22(12):703-22. DOI: 10.1038/s41568-022-00513-x.
31. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. Gut. 2020; 69(8):1510-9. DOI: 10.1136/gutjnl-2019-320204.
32. Ramirez J, Guarner F, Bustos Fernandez L, Maruy A, Sdepanian VL, Cohen H. Antibiotics as Major Disruptors of Gut Microbiota. Front Cell Infect Microbiol. 2020; 10:572912. DOI: 10.3389/fcimb.2020.572912.
33. Zhang X, Li Q, Xia S, He Y, Liu Y, Yang J, et al. Proton Pump Inhibitors and Oral-Gut Microbiota: From Mechanism to Clinical Significance. Biomedicines. 2024; 12(10):2271. DOI: 10.3390/biomedicines12102271.
34. Shahid Z, Epstein DJ. Noninfectious causes of fever in hematologic malignancies. Are antibiotics still indicated? Curr Opin Infect Dis. 2023; 36(4):209-17. DOI: 10.1097/QCO.0000000000000940.
35. Lanckohr C, Bracht H. Antimicrobial stewardship. Curr Opin Crit Care. 2022; 28(5):551-6. DOI: 10.1097/MCC.0000000000000967.
36. Galloway-Peña JR, Shi Y, Peterson CB, Sahasrabhojane P, Gopalakrishnan V, Brumlow CE, et al. Gut Microbiome Signatures Are Predictive of Infectious Risk Following Induction Therapy for Acute Myeloid Leukemia. Clin Infect Dis. 2020; 71(1):63-71. DOI: 10.1093/cid/ciz777.
37. Webb BJ, Majers J, Healy R, Jones PB, Butler AM, Snow G, et al. Antimicrobial Stewardship in a Hematological Malignancy Unit: Carbapenem Reduction and Decreased Vancomycin-Resistant Enterococcus Infection. Clin Infect Dis. 2020; 71(4):960-7. DOI: 10.1093/cid/ciz900.
38. Rashidi A, Karuppiah S, Ebadi M, Shanley R, Khoruts A, Weisdorf DJ, et al. A dose-finding safety and feasibility study of oral activated charcoal and its effects on the gut microbiota in healthy volunteers not receiving antibiotics. PLoS One. 2022; 17(6):e0269986. DOI: 10.1371/journal.pone.0269986.
39. Gosselin S, Hoegberg LCG, Hoffman RS. Gut decontamination in the poisoned patient. Br J Clin Pharmacol. 2025; 91(3):595-603. DOI: 10.1111/bcp.16379.
40. Li S, Yakabe K, Zai K, Liu Y, Kishimura A, Hase K, et al. Specific adsorption of a β-lactam antibiotic in vivo by an anion-exchange resin for protection of the intestinal microbiota. Biomater Sci. 2021; 9(21):7219-27. DOI: 10.1039/d1bm00958c.
41. de Gunzburg J, Ducher A, Modess C, Wegner D, Oswald S, Dressman J, et al. Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: A proof of concept study in healthy subjects. J Clin Pharmacol. 2015; 55(1):10-6. DOI: 10.1002/jcph.359.
42. Quan M, Zhang X, Fang Q, Lv X, Wang X, Zong Z. Fighting against Clostridioides difficile infection: Current medications. Int J Antimicrob Agents. 2024; 64(1):107198. DOI: 10.1016/j.ijantimicag.2024.107198.
43. Kokai-Kun JF, Roberts T, Coughlin O, Le C, Whalen H, Stevenson R, et al. Use of ribaxamase (SYN-004), a β-lactamase, to prevent Clostridium difficile infection in β-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect Dis. 2019; 19(5):487-96. DOI: 10.1016/S1473-3099(18)30731-X.
44. Delavy M, Burdet C, Sertour N, Devente S, Docquier JD, Grall N, et al.; PrediRes Study Group. A Clinical Study Provides the First Direct Evidence That Interindividual Variations in Fecal β-Lactamase Activity Affect the Gut Mycobiota Dynamics in Response to β-Lactam Antibiotics. mBio. 2022; 13(6):e0288022. DOI: 10.1128/mbio.02880-22.
45. Reigadas E, van Prehn J, Falcone M, Fitzpatrick F, Vehreschild MJGT, Kuijper EJ,et al; European Society of Clinical Microbiology and Infectious Diseases Study Group on Clostridioides difficile (ESGCD) and Study Group for Host and Microbiota interaction (ESGHAMI). How to: prophylactic interventions for prevention of Clostridioides difficile infection. Clin Microbiol Infect. 2021; 27(12):1777-83. DOI: 10.1016/j.cmi.2021.06.037.
46. Yu Y, Wang W, Zhang F. The Next Generation Fecal Microbiota Transplantation: To Transplant Bacteria or Virome. Adv Sci (Weinh). 2023; 10(35):e2301097. DOI: 10.1002/advs.202301097.
47. van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013; 368(5):407-15. DOI: 10.1056/NEJMoa1205037.
48. Minkoff NZ, Aslam S, Medina M, Tanner-Smith EE, Zackular JP, Acra S, et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst Rev. 2023; 4(4):CD013871. DOI: 10.1002/14651858.CD013871.pub2.
49. Cheng YW, Fischer M. Fecal Microbiota Transplantation. Clin Colon Rectal Surg. 2023; 36(2):151-6. DOI: 10.1055/s-0043-1760865.
50. Yadegar A, Bar-Yoseph H, Monaghan TM, Pakpour S, Severino A, Kuijper EJ, et al. Fecal microbiota transplantation: current challenges and future landscapes. Clin Microbiol Rev. 2024; 37(2): e0006022. DOI: 10.1128/cmr.00060-22.
51. Belvoncikova P, Maronek M, Gardlik R. Gut Dysbiosis and Fecal Microbiota Transplantation in Autoimmune Diseases. Int J Mol Sci. 2022; 23(18):10729. DOI: 10.3390/ijms231810729.
Descargas
Publicado
Número
Sección
Licencia
Derechos de autor 2026 Justo Alejandro Porras-Torres
Esta obra está bajo una licencia internacional Creative Commons Atribución 4.0.
La Revista Salutem Scientia Spiritus usa la licencia Creative Commons de Atribución – No comercial – Sin derivar: Los textos de la revista son posibles de ser descargados en versión PDF siempre que sea reconocida la autoría y el texto no tenga modificaciones de ningún tipo.
